Healthcare Asia on MSN2h
NUHCS to start using breakthrough drug for rare lung condition
Winrevair, which treats hypertension from constricted lung arteries, costs $3,700-$6,730 The National University Heart Centre ...
Pulmonaryhypertensionnews.com19h
After 25 years, I’m still absorbing lessons from chronic illness
Columnist Anna Jeter was recently reminded that she's still absorbing lessons from her chronic illness after 25 years of ...
Is shortness of breath during everyday activities a warning sign of pulmonary hypertension?
Pulmonary hypertension (PH), a serious lung and heart condition, elevates blood pressure in lung arteries, causing shortness ...
C&EN1d
How a hypertension drug can save limbs from frostbite
When frostbitten limbs warm up again, blood rushes back into the tissue. With that blood come compounds such as histamines ...
Managed Healthcare Executive1d
Patients with PAH Who Get Sepsis Experience Care Differences
New data suggests clinicians may be slower to recognize sepsis in people with pulmonary arterial hypertension.
The American Journal of Managed Care2d
Social Isolation Linked to Increased Mortality in Patients With COPD
Social isolation significantly increases the risk of mortality in patients with chronic obstructive pulmonary disease (COPD), ...
GlobalData on MSN3d
MSD’s trial of drug for pulmonary arterial hypertension meets primary endpoint
An independent data monitoring committee has recommended terminating the ZENITH study early based on the results.
Hypertension is a ‘silent killer.’ Here’s what your blood pressure should be at every age
Over time, hypertension can lead to serious medical problems including stroke, heart attack, and kidney failure.
BioPharma Dive3d
New data could help Merck expand use of cardiovascular drug
Positive study results for Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent ...
Business Wire3d
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim ...
Merck's therapy for rare lung condition shown to help reduce risk of death in study
Winrevair was approved to treat pulmonary arterial hypertension (PAH), a progressive disorder caused by a constriction of ...
The American Journal of Managed Care4d
Communication Can Boost Medication Persistence in PAH
Patients continued taking their medications for pulmonary arterial hypertension (PAH) when symptoms appeared to improve, ...